Tissue-type plasminogen activator therapy versus primary coronary angioplasty: Impact on myocardial tissue perfusion and regional function 1 month after uncomplicated myocardial infarction

被引:43
|
作者
Agati, L
Voci, P
Hickle, P
Vizza, DC
Autore, C
Fedele, F
Feinstein, SB
Dagianti, A
机构
[1] Univ Roma La Sapienza, Dept Cardiol & Cardiac Surg, I-00161 Rome, Italy
[2] Univ Illinois, Dept Cardiol, Chicago, IL USA
关键词
D O I
10.1016/S0735-1097(97)00487-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives. This study sought to compare the impact of primary coronary angioplasty and thrombolytic therapy for acute myocardial infarction (AMI) on 1-month infarct size and microvascular perfusion. Background. The effect of the reperfusion strategies of primary coronary angioplasty and thrombolytic therapy on microvascular integrity still remains to be determined. Methods. Sixty two consecutive patients with a first AMI, undergoing intravenous tissue-type plasminogen activator (t-PA) therapy (32 patients, Group I) or primary angioplasty (30 patients, Group II), were studied. Only patients with 1-month Thrombolysis in Myocardial Infarction (TIMI) flow grade 2 or 3 were selected for the study, Patients in whom primary angioplasty was unsuccessful or those with clinical evidence of failed reperfusion were excluded. Microvascular perfusion was assessed at 1 month by intracoronary injection of sonicated microbubbles. Contrast score index (CSI) and wall motion score index (WMSI) were derived using qualitative methods. Results. At baseline there were no significant differences between groups for age, risk factors, time to hospital presentation, Killip class on admission, prevalence of multivessel disease or anterior infarct site, infarct area extension before reperfusion, peak creatine kinase levels and postinfarction treatment. Conversely, significant differences between groups were found at follow-up for percent residual infarct related-artery (IRA) stenosis (70 +/- 12 vs 36 +/- 14 [mean +/- SD], p = 0.0001), CSI (1.02 +/- 0.4 vs. 1.49 +/- 0.5, p = 0.0003) and WMSI (1.67 +/- 0.3 vs. 1.45 +/- 0.3, p = 0.015). In particular, in the subset of patients with TIMI grade 3 flow, a perfusion defect occurred in one or more segments subtended by the IRA in 72% of Group I versus 31% of Group II patients (p < 0.00001) and in 27% of Group I versus 8% of Group II segments (p < 0.00001), Conclusions. The present study shows, in a highly selected cohort with successful IRA recanalization, that primary angioplasty is more effective than thrombolysis in preserving microvascular flow and preventing extension of myocardial damage at 1-month after AMI. (C) 1998 by the American College of Cardiology.
引用
收藏
页码:338 / 343
页数:6
相关论文
共 50 条
  • [41] ABRUPT RECURRENT THROMBOSIS AFTER INTRAVENOUS TISSUE PLASMINOGEN-ACTIVATOR AND EMERGENCY CORONARY ANGIOPLASTY IN ACUTE MYOCARDIAL-INFARCTION
    STACK, RS
    TOPOL, EJ
    ONEILL, WW
    GEORGE, BS
    CANDELA, RJ
    KEREIAKES, DJ
    ABBOTTSMITH, CW
    CALIFF, RM
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1987, 9 (02) : A232 - A232
  • [42] CONCURRENT NITROGLYCERIN THERAPY IMPAIRS TISSUE-TYPE PLASMINOGEN ACTIVATOR-INDUCED THROMBOLYSIS IN PATIENTS WITH ACUTE MYOCARDIAL-INFARCTION
    NICOLINI, FA
    FERRINI, D
    OTTANI, F
    GALVANI, M
    RONCHI, A
    BEHRENS, PH
    RUSTICALI, F
    MEHTA, JL
    AMERICAN JOURNAL OF CARDIOLOGY, 1994, 74 (07): : 662 - 666
  • [43] MONITORING OF FIBRIN GENERATION DURING THROMBOLYTIC THERAPY OF ACUTE MYOCARDIAL-INFARCTION WITH RECOMBINANT TISSUE-TYPE PLASMINOGEN-ACTIVATOR
    RAPOLD, HJ
    KUEMMERLI, H
    WEISS, M
    BAUR, H
    HAEBERLI, A
    CIRCULATION, 1989, 79 (05) : 980 - 989
  • [44] USEFULNESS OF LATE CORONARY THROMBOLYSIS (RECOMBINANT TISSUE-TYPE PLASMINOGEN-ACTIVATOR) IN PRESERVING LEFT-VENTRICULAR FUNCTION IN ACUTE MYOCARDIAL-INFARCTION
    VILLARI, B
    PISCIONE, F
    BONADUCE, D
    GOLINO, P
    LANZILLO, T
    CONDORELLI, M
    CHIARIELLO, M
    AMERICAN JOURNAL OF CARDIOLOGY, 1990, 66 (19): : 1281 - 1286
  • [45] RANDOMIZED CONTROLLED TRIAL OF LATE IN-HOSPITAL ANGIOGRAPHY AND ANGIOPLASTY VERSUS CONSERVATIVE MANAGEMENT AFTER TREATMENT WITH RECOMBINANT TISSUE-TYPE PLASMINOGEN-ACTIVATOR IN ACUTE MYOCARDIAL-INFARCTION
    BARBASH, GI
    ROTH, A
    HOD, H
    MODAN, M
    MILLER, HI
    RATH, S
    ZAHAV, YH
    KEREN, G
    MOTRO, M
    SHACHAR, A
    BASAN, S
    AGRANAT, O
    RABINOWITZ, B
    LANIADO, S
    KAPLINSKY, E
    AMERICAN JOURNAL OF CARDIOLOGY, 1990, 66 (05): : 538 - 545
  • [46] A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction (vol 336, pg 1621, 1997)
    Betriu, A
    NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (04): : 287 - 287
  • [47] RECOMBINANT TISSUE-TYPE PLASMINOGEN-ACTIVATOR AND IMMEDIATE ANGIOPLASTY IN ACUTE MYOCARDIAL-INFARCTION - ONE-YEAR FOLLOW-UP
    ARNOLD, AER
    SIMOONS, ML
    VANDEWERF, F
    DEBONO, DP
    LUBSEN, J
    TIJSSEN, JGP
    SERRUYS, PW
    VERSTRAETE, M
    CIRCULATION, 1992, 86 (01) : 111 - 120
  • [48] Direct coronary angioplasty versus thrombolytic therapy for acute myocardial infarction: Impact on microvascular integrity and regional function
    Agati, L
    Hickle, P
    Voci, P
    Darwish, Y
    Autore, C
    Feinstein, SB
    CIRCULATION, 1996, 94 (08) : 3361 - 3361
  • [49] RECOMBINANT TISSUE-TYPE PLASMINOGEN-ACTIVATOR IN ACUTE MYOCARDIAL-INFARCTION - ROLE OF THE CRITICAL CARE NURSE
    KLINE, EM
    HEART & LUNG, 1987, 16 (06): : 779 - 786
  • [50] Polymorphism in the gene coding for tissue-type plasminogen activator (t-PA) and risk of future myocardial infarction
    Baker, MT
    Vaughan, DE
    Hennekens, CH
    Stampfer, MJ
    Ridker, PM
    CIRCULATION, 1996, 94 (08) : 2688 - 2688